Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Conflict of interest The author has provided advisory services to AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk, and has received lecture honoraria from Bristol Myers Squibb, Novartis and the above-mentioned companies
From plant-based blends to whey isolates packed with BCAAs, there's something for nearly every diet, goal and taste preference
Exenatide, the first GLP-1RA approved in 2005, demonstrated clinical efficacy but its low homology with human GLP-1 and gastrointestinal side effects restricted widespread use (Muttenthaler et al., 2021)
Retas structure allows for consistent receptor binding affinity and reliable results across a range of experimental models
US$ 24.33
US$ 20.34
US$ 22.83
US$ 1554.57
Sold : Login>>
